Synthesis of 14-alkoxymorphinan derivatives and their pharmacological actions

Topics in Current Chemistry

Volumn 299, Issue , 2011, Pages 63-91

  Schmidhammer, Helmut ^a   Spetea, Mariana ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

14 Alkoxymorphinans; Opioid agonist; Opioid antagonist; Opioid receptors; Opioids

Indexed keywords

MORPHINAN DERIVATIVE;

ANIMAL; ARTICLE; HUMAN; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; HUMANS; MORPHINANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79551480640     PISSN: 03401022     EISSN: None     Source Type: Book Series    
DOI: 10.1007/128_2010_77     Document Type: Article

References (106)

1. Evans CJ (2004) Secrets of opium poppy revealed. Neuropharmacology 47:293-299
2. Kieffer BL, Evans CJ (2009) Opioid receptors: from binding sites to visible molecules in vivo. Neuropharmacology 56:205-212
3. Mansour A, Fox CA, Akil H, Watson SJ (1995) Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications. Trends Neurosci 18:22-29
4. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ (2001) Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 62:111-123
5. Stein C (2003) Opioid receptors on peripheral sensory neurons. Adv Exp Med Biol 521:69-76
6. Holzer P (2009) Opioid receptors in the gastrointestinal tract. Regul Pept 155:11-17
7. Kieffer BL, Gaveriaux-Ruff C (2002) Exploring the opioid system by gene knockout. Prog Neurobiol 66:285-306
8. Bodnar RJ (2009) Endogenous opiates and behavior: 2008. Peptides 30:2432-2479
9. Zimmerman DM, Leander JD (1990) Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents. J Med Chem 33:895-902
10. Takemori AE, Portoghese PS (1992) Selective naltrexone-derived opioid receptors antagonists. Annu Rev Pharmacol Toxicol 32:239-269
11. Borsodi A, Toth G (1995) Characterization of opioid receptor types and subtypes with new ligands. Ann NY Acad Sci 757:339-352
12. Schmidhammer H (1998) Opioid receptor antagonists. In: Ellis GP, Luscombe DK, Oxford AW (ed)s) Prog Med Chem 35:83-132
13. Schiller PW, Weltrowska G, Berezowska I, Nguyen TM, Wilkes BC, Lemieux C, Chung NN (1999) The TIPP opioid peptide family: development of d antagonists, d agonists, and mixed m agonist/d antagonists. Biopolymers 51:411-425
14. DeHaven-Hudkins DL, Dolle RE (2004) Peripherally restricted agonists as novel analgesic agents. Curr Pharm Design 10:743-757
15. Eguchi M (2004) Recent advances in selective opioid receptor agonists and antagonists. Med Res Rev 24:182-212
16. Metcalf MD, Coop A (2005) Kappa opioid antagonists: past successes and future prospects. AAPS J 7:E704-E722
17. Schiller PW (2005) Opioid peptide-derived analgesics. AAPS J 7:E560-E565
18. Goodman AJ, Le Bourdonnec B, Dolle RE (2007) Mu opioid receptor antagonists: recent developments. Chem Med Chem 2:1552-1557
19. Fürst S, Hosztafi S (2008) The chemical and pharmacological importance of morphine analogues. Acta Physiol Hung 95:3-44
20. Trescot AM, Datta S, Lee M, Hansen H (2008) Opioid pharmacology. Pain Physician 11: S133-S153
21. Nicholson B (2009) Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain. Pain Pract 9:71-81
22. Blumberg H, Dayton HB, Wolf PS (1966) Counteraction of narcotic antagonist analgesics by the narcotic antagonist naloxone. Proc Soc Exp Biol Med 123:755-758
23. Resnick RB, Volavka J, Freedman AM, Thomas M (1974) Studies of EN-1639A (naltrex-one): a new narcotic antagonist. Am J Psychiatry 131:646-650
24. O'Malley SS (1996) Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. Alcohol Alcohol Suppl 1:77-81
25. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E (2001) Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 96:1565-1573
26. Brown DR, Goldberg LI (1985) The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 24:181-191
27. Viscusi ER, Gan TJ, Leslie JB, Foss JF, Talon MD, Du W, Owens G (2009) Peripherally acting m-opioid receptor antagonists and postoperative ileus: mechanisms of action and clinical applicability. Anesth Analg 108:1811-1822
28. Nagase H, Hayakawa J, Kawamura K, Kawai K, Takezawa Y, Matsuura H, Tajima C, Endo T (1998) Discovery of a structurally novel opioid kappa-agonist derived from 4, 5-epoxymorphinan. Chem Pharm Bull 46:366-369
29. Nakao K, Mochizuki H (2009) Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients. Drugs Today 45:323-329
30. Coop A, Rice KC (2000) Role of d-opioid receptors in biological processes. Drug News Perspect 13:481-487
31. Sadée W, Wang D, Bilsky EJ (2005) Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci 76:1427-1437
32. Cunningham CW, Coop A (2006) Therapeutic applications of opioid antagonists. Chem Today 24:54-57
33. Schmidhammer H, Burkard WP, Eggstein-Aeppli L, Smith CFC (1989) Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(cyclopropylmethyl)- 4, 14-dimethoxy-morphinan-6-one, a selective m opioid receptor antagonist. J Med Chem 32:418-421
34. Portoghese PS, Sultana M, Takemori AE (1988) Naltrindole, a highly selective and potent non-peptide d-opioid receptor antagonist. Eur J Pharmacol 146:185-186
35. Portoghese PS, Lipkowski AW, Takemori AE (1987) Binaltorphimine and nor-binaltorphi-mine, potent and selective k-opioid receptor antagonists. Life Sci 40:1287-1292
36. Heinisch G, Klintz V, Viehböck F (1971) Methanolysis of 14-bromocodeinone dimethyl acetale. Monatsh Chem 102:530-539
37. Razdan RK, Ghosh AC (1980) US Patent No 4,232,028
38. Kobylecki RJ, Carling RW, Lord JAH, Smith CFC, Lane AC (1982) Common anionic receptor site hypothesis: its relevance to the antagonist action of naloxone. J Med Chem 25:116-120
39. Razdan RK, Ghosh AC (1980) UK Patent No 2,045,758
40. Ghosh AC, Razdan RK (1982) US Patent No 4,362,733
41. Schmidhammer H, Aeppli L, Atwell L, Fritsch F, Jacobson AE, Nebuchla M, Sperk G (1984) Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (-)-14-methoxy-N-methylmorphinan- 6-ones. J Med Chem 27:1575-1579
42. Schmidhammer H, Jennewein HK, Krassnig R, Traynor JR, Patel D, Bell K, Froschauer G, Mattersberger K, Jachs-Ewinger C, Jura P, Fraser GL, Kalinin VN (1995) Synthesis and biological evaluation of 14-alkoxymorphinans. 11. 3-Hydroxycyprodime and analogues: opioid antagonist profile in comparison to cyprodime. J Med Chem 38:3071-3077
43. Schütz J, Dersch CM, Horel R, Spetea M, Koch M, Meditz R, Greiner E, Rothman RB, Schmidhammer H (2002) Synthesis and biological evaluation of 14-alkoxymorphinans. 17. Highly d opioid receptor selective 14-alkoxy- substituted indolo- and benzofuromorphinans. J Med Chem 45:5378-5383
44. Greiner E, Spetea M, Krassnig R, Schüllner F, Aceto M, Harris LS, Traynor JR, Woods JH, Coop A, Schmidhammer H (2003) Synthesis and biological evaluation of 14-alkoxymorphi-nans. 18. N-Substituted 14-phenylpropoxymorphinan- 6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships. J Med Chem 46:1758-1763
45. Schütz J, Spetea M, Koch M, Aceto MD, Harris LS, Coop A, Schmidhammer H (2003) Synthesis and biological evaluation of 14-alkoxymorphinans. 20. 14-Phenylpropoxymeto-pon: an extremely powerful analgesic. J Med Chem 46:4182-4187
46. Cami-Kobeci G, Neal AP, Bradbury FA, Purington LC, Aceto MD, Harris LS, Lewis JW, Traynor JR, Husbands SM (2009) Mixed k/m opioid receptor agonists: the 6b-naltrexamines. J Med Chem 52:1546-1552
47. Lattanzi R, Spetea M, Schüllner F, Rief SB, Krassnig R, Negri L, Schmidhammer H (2005) Synthesis and biological evaluation of 14-alkoxymorphinans. 22. Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities. J Med Chem 48:3372-3378
48. Schüllner F, Meditz R, Krassnig R, Morandell G, Kalinin VN, Sandler E, Spetea M, White A, Schmidhammer H, Berzetei-Gurske IP (2003) Synthesis and biological evaluation of 14-alkoxymorphinans. 19. Effect of 14-O-benzylation on the opioid receptor affinity and antagonist potency of naltrexone. Helv Chim Acta 86:2335-2341
49. Schmidhammer H, Daurer D, Wieser M, Monory K, Borsodi A, Elliott J, Traynor JR (1997) Synthesis and biological evaluation of 14-alkoxymorphinans. 14. 14-Ethoxy-5-methyl substituted indolomorphinans with d opioid receptor selectivity. Bioorg Med Chem Lett 7:151-156
50. Biyashev D, Monory K, Benyhe S, Schütz J, Koch M, Schmidhammer H, Borsodi A (2001) Novel delta-opioid-receptor-selective ligands in the 14-alkoxy-substituted indolo- and ben-zofuromorphinan series. Helv Chim Acta 84:2015-2021
51. Portoghese PS, Sultana M, Nagase H, Takemori AE (1988) Application of the message-address concept in the design of highly potent and selective non-peptide d opioid receptor antagonists. J Med Chem 31:281-282
52. Portoghese PS, Nagase H, Maloney Huss KE, Lin C-E, Takemori AE (1991) Role of spacer and address components in peptidomimetic d opioid receptor antagonists related to naltrin-dole. J Med Chem 34:1715-1720
53. Schmidhammer H, Schwarz P, Wei Z-Y (1998) A novel and efficient synthesis of 14-alkoxy-substituted indolo- and benzofuromorphinans in the series of selective d opioid receptor antagonists. Helv Chim Acta 81:1215-1222
54. Pasternak GW, Hahn EF (1980) Long-acting opiate agonists and antagonists: 14-hydroxy-dihydromorphinone hydrazones. J Med Chem 23:674-676
55. 3H-oxymorphazone to rat brain membranes. Life Sci 40:1579-1588
56. 3H)naloxone binding sites by C-6 derivatives of morphinan-6-ones. Life Sci 48:439-451
57. 3H]-naloxone binding sites in rat brain. Pharm Res 25:31-32
58. Fürst S, Hosztafi S, Friedmann T (1995) Structure-activity relationships of synthetic and semisynthetic opioid agonists and antagonists. Curr Med Chem 1:423-440
59. Monory K, Greiner E, Sartania N, Sallai L, Pouille Y, Schmidhammer H, Hanoune J, Borsodi A (1999) Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans. Life Sci 64:2011-2020
60. Gergely A, Gyimesi-Forras K, Horvath P, Hosztafi S, Kökösi J, Nagy PI, Szasz G, Szentesi A (2004) 6-Oxo-morphinane oximes: pharmacology, chemistry and analytical application. Curr Med Chem 11:2555-2564
61. Oldenziel OH, van Leusen D, van Leusen AM (1977) Chemistry of solfonylmethyl isocya-nides. 13. A general one-step synthesis of nitriles from ketones using tosylmethyl isocyanide. Introduction of a one-carbon unit. J Org Chem 42:3114-3118
62. Greiner E, Schottenberger H, Wurst K, Schmidhammer H (2001) Novel class of morphinans with acrylonitrile incorporated substructures as key intermediates for non-oxygen-bridged opioid ligands. J Am Chem Soc 123:3840-3841
63. Schütz J, Windisch P, Kristeva E, Wurst K, Ongania K-H, Horvath UIE, Schottenberger H, Laus G, Schmidhammer H (2005) Mechanistic diversity of the van Leusen reaction applied to 6-ketomorphinans and synthetic potential of the resulting acrylonitrile substructures. J Org Chem 70:5323-5326
64. Botros S, Lipkowski AW, Larson DL, Stark AP, Takemori AE, Portoghese PS (1989) Opioid agonist and antagonist activities of peripherally selective derivatives of naltrexamine and oxymorphamine. J Med Chem 32:2068-2071
65. 1 opioid receptor-mediated antinociception in mice. J Med Chem 38:402-407
66. Schütz J, Brandt W, Spetea M, Wurst K, Wunder G, Schmidhammer H (2003) Synthesis of 6-amino acid substituted derivatives of the highly potent analgesic 14-O-methyloxymor-phone. Helv Chim Acta 86:2142-2148
67. Riba P, Friedmann T, Király KP, Al-Khrasani M, Sobor M, Asim MF, Spetea M, Schmidhammer H, Fürst S (2010) Novel approach to demonstrate high efficacy of micro opioids in the rat vas deferens: a simple model of predictive value. Brain Res Bull 81:178-184
68. Fürst S, Riba P, Friedmann T, T́?mar J, Al-Khrasani M, Obara I, Makuch W, Spetea M, Schütz J, Przewlocki R, Przewlocka B, Schmidhammer H (2005) Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat. J Pharmacol Exp Ther 312:609-618
69. Schmidhammer H, Schratz A, Mitterdorfer J (1990) Synthesis and biological evaluation of 14-alkoxymorphinans. 8. 14-Methoxymetopon, an extremely potent opioid agonist. Helv Chim Acta 73:1784-1787
70. Freye E, Schmidhammer H, Latasch L (2000) 14-Methoxymetopon, a potent opioid, induces no respiratory depression, less sedation, and less bradycardia than sufentanil in the dog. Anesth Analg 90:1359-1364
71. Zernig G, Saria A, Krassnig R, Schmidhammer H (2000) Signal transduction efficacy of the highly potent m-opioid agonist 14-methoxymetopon. Life Sci 66:1871-1877
72. Urigüen L, Fernandez B, Romero EM, De Pedro N, Delgado MJ, Guaza C, Schmidhammer H, Viveros MP (2002) Effects of 14-methoxymetopon, a potent opioid agonist, on the responses to the tail electric stimulation test and plus-maze activity in male rats: neuroendocrine correlates. Brain Res Bull 57:661-666
73. King MA, Su W, Nielan C, Chang AH, Schütz J, Schmidhammer H, Pasternak GW (2003) 14-Methoxymetopon, a very potent m-opioid analgesic with an unusual pharmacological profile. Eur J Pharmacol 459:203-209
74. 3H]14-methoxymetopon, a high affinity m-opioid receptor agonist. Eur J Neurosci 18:290-295
75. Bileviciute-Ljungar I, Spetea M, Guo Y, Schütz J, Windisch P, Schmidhammer H (2006) Peripherally mediated antinociception of the m-opioid receptor agonist 2-[(4, 5a-epoxy-3-hydroxy-14b-methoxy-17-methylmorphinan-6b-yl) amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation. J Pharmacol Exp Ther 317:220-227
76. Király KP, Riba P, D'Addario C, Di Benedetto M, Landuzzi D, Candelotti S, Romualdi P, Fürst S (2006) Alterations in prodynorphin gene expression and dynorphin levels in different brain regions after chronic administration of 14-methoxymetopon and oxycodone-6-oxime. Brain Res Bull 70:233-239
77. Mahurter L, Garceau C, Marino J, Schmidhammer H, Toth G, Pasternak GW (2006) Separation of binding affinity and intrinsic activity of the potent m-opioid 14-methoxymetopon. J Pharmacol Exp Ther 319:247-253
78. Sabino V, Cottone P, Steardo L, Schmidhammer H, Zorrilla EP (2007) 14-Methoxymetopon, a highly potent m opioid agonist, biphasically affects ethanol intake in sardinian alcohol-preferring rats. Psychopharmacology 192:537-546
79. Fürst S, Búzás B, Friedmann T, Schmidhammer H, Borsodi A (1993) Highly potent novel opioid receptor agonist in the 14-alkoxymetopon series. Eur J Pharmacol 236:209-215
80. Stegmann GF (1999) Etorphine-halothane anaesthesia in two five-year-old African elephants (Loxodonta africana). J S Afr Vet Assoc 70:164-166
81. Sterken J, Troubleyn J, Gasthuys F, Maes V, Diltoer M, Verborgh C (2004) Intentional overdose of large animal immobilon. Eur J Emerg Med 11:298-301
82. Feinberg AP, Creese I, Snyder SH (1976) The opiate receptor: a model explaining structure-activity relationships of opiate agonists ad antagonists. Proc Natl Acad Sci USA 73:4215-4219
83. Casy AF, Parfitt RT (1986) Opioid analgesics: chemistry and receptors. Plenum, New York
84. Spetea M, Schüllner F, Moisa RC, Berzetei-Gurske IP, Schraml B, Dörfler C, Aceto MD, Harris LS, Coop A, Schmidhammer H (2004) Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the m opioid receptor antagonist cyprodime. J Med Chem 47:3242-3247
85. Spetea M, Greiner E, Aceto MD, Harris LS, Coop A, Schmidhammer H (2005) Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency. J Med Chem 48:5052-5055
86. Stein C, Clark JD, Oh U, Vasko MR, Wilcox GL, Overland AC, Vanderah TW, Spencer RH (2009) Peripheral mechanisms of pain and analgesia. Brain Res Rev 60:90-113
87. Stein C, Schäfer M, Machelska H (2003) Attaching pain at its source: new perspectives on opioids. Nat Med 9:1003-1008
88. Walker JS (2003) Anti-inflammatory effects of opioids. Adv Exp Med Biol 521:148-160
89. Smith HS (2008) Peripherally-acting opioids. Pain Physician 11:S121-S132
90. Iorio MA, Frigni V (1984) Narcotic agonist/antagonist properties of quaternary diastereo-isomers derived from oxymorphone and naloxone. Eur J Med Chem 19:301-303
91. Larson DL, Hua M, Takemori AK, Portoghese PS (1993) Possible contribution of a glutathione conjugate to the long-duration action of b-funaltrexamine. J Med Chem 36:3669-3673
92. Spetea M, Friedmann T, Riba P, Schütz J, Wunder G, Langer T, Schmidhammer H, Fürst S (2004) In vitro opioid activity profiles of 6-amino acid substituted derivatives of 14-O-methyloxymorphone. Eur J Pharmacol 483:301-308
93. Al-Khrasani M, Spetea M, Friedmann T, Riba P, Kiraly K, Schmidhammer H, Fürst S (2007) DAMGO and 6b-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens. Brain Res Bull 74:369-375
94. Obara I, Makuch W, Spetea M, Schütz J, Schmidhammer H, Przewlocki R, Przewlocka B (2007) Local peripheral antinociceptive effects of 14-O-methyloxymorphone derivatives in inflammatory and neuropathic pain in the rat. Eur J Pharmacol 558:60-67
95. Spetea M, Erlandsson Harris H, Berzetei-Gurske IP, Klareskog L, Schmidhammer H (2001) Binding, pharmacological and immunological profiles of the d-selective opioid receptor antagonist HS 378. Life Sci 69:1775-1782
96. D'Ambrosio A, Noviello L, Negri L, Schmidhammer H, Quintieri F (2004) Effect of novel non-peptidic d opioid receptor antagonists on human T and B cell activation. Life Sci 75:63-75
97. Tryoen-Toth P, Decaillot FM, Filliol D, Befort K, Lazarus LH, Schiller PW, Schmidhammer H, Kieffer BL (2005) Inverse agonism and neutral antagonism at wild type and constitutively active mutant d opioid receptors. J Pharmacol Exp Ther 313:410-421
98. Jenny M, Winkler C, Spetea M, Schennach H, Schmidhammer H, Fuchs D (2008) Non-peptidic d-opioid receptor antagonists suppress mitogen-induced tryptophan degradation in peripheral blood mononuclear cells in vitro. Immunol Lett 118:82-87
99. Cao CQ, Hong YG, Dray A, Perkins MN (2001) Selective depression of nociceptive responses of dorsal horn neurones by SNC80 in a perfused hindquarter preparation of adult mouse. Neuroscience 107:329-338
100. Cao CQ, Hong YG, Dray A, Perkins MN (2001) Spinal d opioid receptors mediate suppression of systemic SNC80 on excitability of the flexor reflex in normal and inflamed rat. Eur J Pharmacol 418:79-87
101. Shahbazian A, Heinemann A, Schmidhammer H, Beubler E, Holzer-Petsche U, Holzer P (2002) Involvement of m- and k-, but not d-opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine. Br J Pharmacol 135:741-750
102. Arakawa K, Akami T, Okamoto M, Nakajima H, Mitsuo M, Nakai I, Oka T, Nagase H, Matsumoto S (1992) Immunosuppressive effects of d-opioid receptor antagonist on xenoge-neic mixed lymphocyte response. Transplant Proc 24:696-697
103. Arakawa K, Akami T, Okamoto M, Akioka K, Akai I, Oka T, Nagase H (1993) Immuno-suppression by d opioid receptor antagonist. Transplant Proc 25:738-740
104. 1 opioid receptor antagonist, 7-benzylspiroindanylnaltrexone, prolongs renal allograft survival in a rat model. Eur J Pharmacol 354:R3-R5
105. Gavériaux-Ruff C, Filliol D, Simonin F, Matthes HWD, Kieffer BL (2001) Immunosuppres-sion by d-opioid antagonist naltrindole: d- and triple m/d/k-opioid receptor knockout mice reveal a nonopioid activity. J Pharmacol Exp Ther 298:1193-1198
106. Winkler C, Neurauter G, Schroecksnadel K, Wirleitner B, Fuchs D (2006) Immunomodula-tory effects of plant extracts. In: Govil JN, Singh VK, Arunachalam C (ed)s) Recent progress in medicinal plants, vol 11. Studium, Houston, pp 139-158